Strengthening the Functional and Food Ingredients Business
First written in FY2016. 12 of 18 entries say "Advanced", first in FY2017. Latest entry: 2026-08-07.
2 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The Food Function Research Institute and the Biotics Research Institute were established on 1 June 2025 through the reorganisation and renaming of the former Ingredients Application Research Institute and Basic Research Institute.」
The research structure was reorganised into the Food Function Research Institute and the Biotics Research Institute, giving concrete form to the research base for functional ingredients and bacterial strains. - 2026-05-13AdvancedEarnings presentation
「Revenue increased 25% in the fiscal year ended March 2026 as the market expanded.」
Reported revenue growth in the bacterial strains business for the fiscal year ended March 2026, demonstrating progress as a growth area. - FY2026-H1AdvancedAnnual report
「Ice cream and overseas sales of bacterial strains and infant formula performed well.」
For the functional ingredients and bacterial-strain business, overseas sales of bacterial strains are expanding as one of the growth areas. - FY2024AdvancedAnnual report
「Morinaga obtained approval from Brazil's National Health Surveillance Agency (ANVISA) to use Bifidobacterium BB536 in general foods and approval to make the health-claim labeling "intestinal regulation."」
For functional ingredients, approval was obtained in Brazil for the use of Bifidobacterium BB536 and similar ingredients, as well as for related health-claim labeling. In addition to research findings on functional ingredients, this gives concrete form to their potential use overseas. - FY2024-Q1RestatedAnnual report
「We also continue to see strong interest in functional ingredients, including our proprietary bacterial strains, amid growing health-related needs.」
It continues to report strong interest in functional ingredients such as its proprietary bacterial strains. - FY2022AdvancedAnnual report
「The research findings confirming that Bifidobacterium MCC1274 improves cognitive function in people suspected of having mild cognitive impairment (MCI), and that this effect correlates with the blood parameter HbA1c, were presented at the Alzheimer's Association International Conference 2021 (AAIC2021), held in Denver, United States, from 26 to 30 July 2021.」
Research findings on MCC1274's effect on cognitive function and its correlation with blood HbA1c were published, advancing applications for the functional ingredient. - FY2022-Q1RestatedAnnual report
「Meanwhile, demand for our functional ingredients continued to strengthen amid growing health-related needs.」
It continues to report strong demand for functional ingredients. - FY2021-Q1AdvancedAnnual report
「Meanwhile, demand for our functional ingredients, including Bifidobacterium, strengthened amid growing health-related needs.」
Demand for functional ingredients such as Bifidobacterium strengthened, and the company describes progress in its ingredients business against a backdrop of health-related needs. - FY2020AdvancedAnnual report
「Bifidobacterium BB536 received GRAS clearance for infant use in the United States.」
After receiving notification from the U.S. FDA that there were no concerns regarding Bifidobacterium BB536, the potential for sales in the United States as an ingredient for infant formula and other products expanded. - FY2020-Q3RestatedAnnual report
「We are also pursuing proactive sales promotion for functional ingredients that contribute to health, as well as expanding our overseas business.」
We continue proactive sales promotion for functional ingredients. - FY2020-Q2RestatedAnnual report
「We are also pursuing proactive sales promotion for functional ingredients that contribute to health, as well as expanding our overseas business.」
We continue sales promotion for functional ingredients, highlighting their contribution to health. - FY2020-Q1RestatedAnnual report
「We are also pursuing proactive sales promotion for functional ingredients that contribute to health, as well as expanding our overseas business.」
We continue proactive sales promotion for functional ingredients, highlighting their contribution to health. - FY2019AdvancedAnnual report
「Shield Lactic Acid Bacteria® (Lactobacillus paracasei strain MCC1849) received GRAS clearance in the United States.」
In addition to expanding sales of functional ingredients, Shield Lactic Acid Bacteria received GRAS clearance in the United States, making sales there possible. - FY2018AdvancedAnnual report
「Sales growth for functional ingredients such as Shield Lactic Acid Bacteria, along with growth in baby food, contributed.」
It states that expanded sales of functional ingredients such as Shield Lactic Acid Bacteria contributed to revenue for the period. - FY2017AdvancedAnnual report
「In the functional ingredients field, we are promoting, jointly with research and medical institutions, the production and quality assurance of bifidobacteria, lactoferrin, milk proteins, various whey ingredients, milk peptides, aloe vera ingredients and lactulose; their application in health foods and other products; academic support for their sale as functional ingredients; and clinical application research into the various health functions of these ingredients.」
We are identifying functional ingredients and advancing initiatives spanning manufacturing and quality assurance, product applications, sales support and joint clinical research. - FY2016First statedAnnual report
「Strengthening the Functional and Food Ingredients Business」
One of the four pillars of the future business portfolio under the medium-term management plan. In research and development, the Company is also working on the production, application and sales support of bifidobacteria, lactoferrin and milk proteins, among other products.